N@N

OTTAWA, ONTARIO--(Marketwire - June 28, 2010) - Chemaphor (TSX VENTURE:CFR) announced today commercialization plans for its Oximunol™ Chewables product, a proprietary natural health enhancer ("NHE") for oral use in companion dogs. Following the recent successful outcome of the Oximunol™supplement canine clinical development program, Chemaphor now is beginning to execute product launch and marketing plans. Given market needs and the critical elements to ensure the optimal adoption of the product, a determination has been made to launch this product into the veterinary channel as a complementary medicine and wellness product. To support this launch, Chemaphor is working with industry leaders in the sales, marketing, and veterinary communities. Accordingly, a series of veterinary interviews has been undertaken to ensure the Oximunol™supplement meets the expectations of veterinarians and the canines in their care to help maximize the desirability and acceptance of the product by dog owners. Positive feedback from these sessions regarding the potential benefits to owners of providing Oximunol™ Chewables to their dogs is driving completion of the final product launch, marketing, and sales plan, in addition to establishing final manufacturing product volumes. With the recent announcement of the Vet-Stem stem cell licensing arrangement, Chemaphor is evaluating the establishment of a sales team to promote the use of Oximunol™ Chewables as well as the Vet-Stem products for companion animals. Mr David Hankinson, Chairman of the Board of Chemaphor, commented "It is exciting for Chemaphor to be entering the commercialization stage with Oximunol™ Chewables after over 10 years of scientific evaluation of the active ingredient, OxC-beta. The Oximunol™ Chewables product fits very nicely into the Chemaphor portfolio of NHE products being developed to assist animals and humans to achieve and maintain wellness."

About Oximunol™Chewables

Oximunol™ Chewables contain OxC-beta, a proprietary mixture of carotenoid oxidation products. Oxidized derivatives of carotenoids occur extensively in the plant world in minute amounts and, as such, are a natural part of the diet. OxC-beta is obtained via the spontaneous, full oxidation of ß-carotene. Uses for OxC-beta and other oxidized carotenoid products are protected by patents owned by Chemaphor in multiple jurisdictions. Additionally, Chemaphor has filed patent applications directed to products containing OxC-beta and its use for enhancing and maintaining the wellness of companion animals.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering NHE products to humans and animals to assist in optimizing health and daily quality of life. Chemaphor is advancing NHE product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at [ www.chemaphor.com ].

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Chemaphor's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Chemaphor or its management. The forward-looking statements are not historical facts, but reflect Chemaphor's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.